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Abstract
Background:  Previous studies of individual genes have shown that in a self-enforcing way,
dimethylation at histone 3 lysine 9 (dimethyl-H3K9) and DNA methylation cooperate to maintain
a repressive mode of inactive genes. Less clear is whether this cooperation is generalized in
mammalian genomes, such as mouse genome. Here we use epigenomic tools to simultaneously
interrogate chromatin modifications and DNA methylation in a mouse leukemia cell line, L1210.
Results: Histone modifications on H3K9 and DNA methylation in L1210 were profiled by both
global CpG island array and custom mouse promoter array analysis. We used chromatin
immunoprecipitation microarray (ChIP-chip) to examine acetyl-H3K9 and dimethyl-H3K9. We
found that the relative level of acetyl-H3K9 at different chromatin positions has a wider range of
distribution than that of dimethyl-H3K9. We then used differential methylation hybridization
(DMH) and the restriction landmark genome scanning (RLGS) to analyze the DNA methylation
status of the same targets investigated by ChIP-chip. The results of epigenomic profiling, which have
been independently confirmed for individual loci, show an inverse relationship between DNA
methylation and histone acetylation in regulating gene silencing. In contrast to the previous notion,
dimethyl-H3K9 seems to be less distinct in specifying silencing for the genes tested.
Conclusion: This study demonstrates in L1210 leukemia cells a diverse relationship between
histone modifications and DNA methylation in the maintenance of gene silencing. Acetyl-H3K9
shows an inverse relationship between DNA methylation and histone acetylation in regulating gene
silencing as expected. However, dimethyl-H3K9 seems to be less distinct in relation to promoter
methylation. Meanwhile, a combination of epigenomic tools is of help in understanding the
heterogeneity of epigenetic regulation, which may further our vision accumulated from single-gene
studies.
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Background
It is well known that DNA methylation plays a repressive
role in gene transcription, both in heterochromatin and in
repressed, protein-coding, euchromatin [1]. Recent work
demonstrated that DNA methylation cooperates with his-
tone modifications to perform this repressive function
[2]. Acetylation and methylation on histone 3 lysine 9
(acetyl-H3K9 and methyl-H3K9, respectively) are two of
the best studied modifications. Acetyl-H3K9 is known to
be associated with active transcription, and methyl-H3K9
with repressed transcription [3]. To better understand the
mechanisms of epigenetic regulation, it is necessary to
clarify the crosstalk, including the distribution patterns,
between these epigenetic markers [3]. Some reports
showed the physical interaction between histone deacety-
lase and histone methyltransferase [4,5]. Meanwhile,
removal of acetylation has been shown to be a necessary
step for histone methyltransferase activity [4,5]. It is
believed that histone acetylation and histone methylation
act in concert to regulate gene transcription. Studies in
fungi and plant, and, to a lesser degree, in mammals indi-
cate that methyl-H3K9 may control DNA methylation in
heterochromatin [6-8]. Current knowledge also supports
the idea that repressive complexes, containing both
methyl binding domain (MBD) proteins and histone
deacetylases (HDACs), in combination with other repres-
sor proteins, direct DNA methylation and subsequently
transcriptional repression [9]. Additional evidence shows
that DNA methylation impacts histone methylation and
that DNA methylation might exert a positive feedback on
lysine methylation [10-14]. To reconcile these two seem-
ingly distinct mechanisms, a self-enforcing network of
epigenetic regulation has been proposed: histone methyl-
ation impacts DNA methylation and histone acetylation
which in turn impacts histone methylation [3,9].
The current self-enforcing model implies close correlation
of histone modifications and DNA methylation, espe-
cially the crosstalk between methyl-H3K9 and DNA meth-
ylation [3]. However, recent reports demonstrated that
these epigenetic markers have varying degrees of auton-
omy [10,15-22]. For example in Arabidopsis, Trichostatin A
(TSA), a histone deacetylase inhibitor, and 5'-aza-2-deox-
ycytidine (AzadC), a demethylating agent, do not always
produce redundant outcomes. Most surprisingly, they
may even demonstrate antagonistic effects as opposed to
the expected synergistic effects [16]. In Arabidopsis, where
DNA methylation is not crucial for survival, methyl-H3K9
marks heterochromatin independent of DNA methyla-
tion [10]. In mammals, no close association between
methyl-H3K9 and DNA methylation was discovered for:
imprinted gene loci on distal chromosome 7 [17,18], the
inactive X chromosome in ICF and Rett syndrome cells
[19], FMR1 in fragile X syndrome [22], or MGMT, LHR in
human cancers [20,21].
Here we analyze profiles of DNA methylation and histone
modifications in a mouse leukemia genome to better
understand the relationship between these epigenetic
events. Using genome-wide data, we demonstrate that his-
tone acetylation and histone methylation show a distinct
degree of autonomy with respect to promoter methyla-
tion.
Results
Global profiling of acety-H3K9, dimethyl-H3K9, and DNA 
methylation in L1210 cells
We first performed chromatin ChIP-chip on the mouse
leukemia cell line, L1210, with antibodies detecting either
acetyl-H3K9 or dimethyl-H3K9. ChIP products were
hybridized onto the mouse 9.2K CpG island microarray.
Immunoprecipitated DNAs from acetyl- or dimethyl-
H3K9 ChIPs were compared individually with total
genomic DNA input. Increased hybridization signals indi-
cated an enrichment of a specific histone modification for
a given CpG island locus (red signals in Figure 1A and 1B).
The scatter plot, with fold changes plotted against geomet-
ric mean of signal intensities, showed that the relative
level of acetyl-H3K9 has a wider range of distribution than
the intensity index seen for dimethyl-H3K9 (Figure 1C
and 1D).
Next, DMH was performed using the mouse CpG island
microarray. Because L1210 originated from the mouse
strain DBA2, we used genomic DNA derived from this
mouse strain as a control for assessing DNA methylation
in L1210. The DMH assay was used to evaluate the meth-
ylation status of BstUI and HpaII sites, located within or
nearby CpG islands. A 2-fold increased intensity was used
as a cutoff for scoring positive loci for DNA methylation
[23]. Those loci scoring positive (>2-fold) in DMH and/or
ChIP-chip data were then used to compare the acety-
H3K9 and dimethyl-H3K9 levels against their promoter
methylation level (Figure 2). Overall, we observed a trend
that high levels of acetyl-H3K9 (>2-fold) were preferen-
tially present in unmethylated CpG islands while acetyla-
tion levels less than 2-fold are correlated with
hypermethylated loci in L1210 (Figure 2A). However, the
distribution pattern of dimethyl-H3K9 against DNA
methylation status was not as distinct as that of acetyl-
H3K9 in this cell line (Figure 2B).
Subpanel profiling of acety-H3K9, dimethyl-H3K9, and 
DNA methylation in L1210 cells
To independently confirm these genome-wide findings,
we focused the epigenetic analysis to a subset of promoter
CpG islands. We first used the restriction landmark
genome scanning (RLGS) technique to identify hyper-
methylated loci in L1210 compared to the control DBA2.
Loss of CpG island sequences in RLGS indicates potential
NotI hypermethylation present in this leukemia cell lineBMC Genomics 2007, 8:131 http://www.biomedcentral.com/1471-2164/8/131
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(Figure 3) [24]. Of the 1300 sites screened, we identified
a total of 435 (or 33%) RLGS fragment losses. The identi-
fied DNA methylation pattern of L1210 was similar to
profiles obtained from the leukemia samples derived
from a mouse model of NK/T acute lymphoblastic leuke-
mia, with numerous commonly methylated sequences
(data not shown) [25].
We then used a subset of 71 (including 54 hypermethyl-
ated loci and 17 unmethylated sequences) promoter CpG
islands identified in RLGS to establish a custom mouse
promoter array for ChIP-chip assays. The 5' fragments of
these targets, including their transcription start site or NotI
restriction site, were amplified by PCR and printed on
glass slides (see Table S1 for location). Immunoprecipi-
tated DNAs from L1210 using antibodies against acetyl-
or dimethyl-H3K9 were then used to hybridize this cus-
tom microarray panel. The results showed that the level of
acetyl-H3K9 had a wider range of distribution than that of
dimethyl-H3K9 (Figure 4A). Similar to the results
obtained from the global microarray, the dimethyl-H3K9
RLGS analysis Figure 3
RLGS analysis. A and B. RLGS sections from L1210 and 
DBA2. Fragment (arrow) was present in DBA2 mouse but 
lost in L1210, indicating that the gene was methylated in 
L1210 and resistant to methylation-sensitive NotI restriction 
enzyme digestion. C and D. Sections showing RLGS fragment 
(arrow) detected in both L1210 and DBA2 mouse, indicating 
that the gene was cut by NotI and not methylated in both 
L1210 and DBA2.
The distribution of histone modifications against DNA meth- ylation identified by ChIP-chip and DMH with CpG island  array Figure 2
The distribution of histone modifications against 
DNA methylation identified by ChIP-chip and DMH 
with CpG island array. A and B. Positive targets (>2-fold 
change) from ChIP-chip (both acetyl-H3K9 and dimethyl-
H3K9) and/or DMH are selected. The histone acetylation 
and methylation levels are plotted against DNA methylation 
status. Histone modification levels in L1210 cells were exam-
ined by comparison between ChIP DNA enriched with 
acetyl- and dimethyl-H3K9 antibody, and the input DNA. 
DNA methylation status was screened by DMH at BstUI and 
HpaII sites. Mean plots with error bounds were used to indi-
cate the level of histone modifications.
The distribution of histone modifications screened by ChIP- chip with mouse CpG island array Figure 1
The distribution of histone modifications screened by 
ChIP-chip with mouse CpG island array. A and B. Rep-
resentative results from the mouse CpG island arrays hybrid-
ized by ChIP DNA, labeled with Cy5, and input control, with 
Cy3. C and D. Scatter plot of histone modification level to 
density index. Histone modification level is indicated by the 
fold enrichment of ChIP DNA vs input DNA.
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level of these 71 loci was not as high as expected even
though most of the targets were methylated in L1210. To
clarify the relationship between histone modifications
and DNA methylation, we plotted the distribution pat-
terns of histone acetylation or methylation versus DNA
methylation in these 71 loci (Figure 4B). Consistent with
the previous reports [26], this interval plot analysis
showed that acety-H3K9 was reversely correlated with
DNA methylation (p < 0.01). However, dimethyl-H3K9
and DNA were not found to be significantly correlated.
Altogether, the results confirmed the aforementioned
genome-wide findings that acetyl-H3K9 and dimethyl-
H3K9 may have distinct autonomies with respect to DNA
methylation in this subpanel of loci in L1210 cells.
Confirmation of acety-H3K9, dimethyl-H3K9, and DNA 
methylation profiles in individual CpG island loci
To further confirm the DNA methylation status and his-
tone modifications in individual genes, combined
bisulfite restriction analysis (COBRA) and ChIP-PCR were
performed on 12 genes chosen from the subpanel list
(Table S2 and Figure 5A). Two known genes, p19ARF and
ID4, were used as unmethylated and methylated controls,
respectively (Figure 5)[25,27]. Of these selected genes, six
were deemed active, while the rest were inactive, accord-
ing to their associated epigenetic marks (Table S2). Of the
12 targets examined, the methylation status of 10 genes
was confirmed in L1210 cells (Figure 5B). Two genes
(BC011343  and  Dscaml1), found to be methylated by
RLGS (Table S1), were not confirmed by COBRA, which
may be caused by different restriction enzymes used in
these two methods. The COBRA data showed an "all or
nothing" methylation status in the promoters of targets
examined. In the tested sites of these promoters, there
seems to be no partial methylation detected by COBRA,
which facilitates our further analysis.
ChIP, followed by real-time PCR, was applied to evaluate
both acetyl- and dimethyl-H3K9 enrichment in the pro-
moter regions of these targets. The enrichment levels of
these 12 loci were compared between ChIP-DNA and
genomic DNA (Figure 5C). Eleven of the 12 loci showed
the same trend of histone modifications as derived by
ChIP-chip assays (Table S2 and Figure 5C). In this regard,
the acetyl-H3K9 level was inversely correlated with the
DNA methylation status. Not surprisingly, the dimethyl-
H3K9 level showed no significant difference with respect
to the DNA methylation status of these loci, suggesting
that the acquisition of dimethyl-H3K9 is less dependent
on DNA methylation in the protein-coding genes than
acetyl-H3K9. Meanwhile, the overall enrichment of
acetyl-H3K9 varied greatly, but dimethy-H3K9 varied to a
lesser extent, which is consistent with our ChIP-chip data.
The results of the two control genes, p19ARF and ID4, are
consistent with our other data (Figure 5C).
The chromatin landscape of the promoter regions (6-kb)
in two genes, Ran  and  Zic3, was analyzed in greater
detailed by ChIP-PCR. Twelve sets of primers were used in
ChIP-PCR to cover their promoter regions from -3.5 to
2.5-kb away from the respective transcription start sites.
The overall levels of acetyl-H3K9 were lower than those of
dimethyl-H3K9 in the promoter region of the inactive
Zic3  gene, but significantly increased in the active Ran
gene in L1210 cells (Figure 6). In contrast, dimethyl-H3K9
levels were only slightly higher than those of acetyl-H3K9
in most parts of the interrogating regions, except in some
regions of the active Ran promoter. The highest level of
dimethyl-H3K9 was found in transcribed regions but not
in the promoter of repressed genes.
The effects of Trichostatin A (TSA) and 5-aza-2'-
deoxycytidine (AzadC) on gene re-expression
Four genes were studied following treatment with TSA, a
histone deacetylase inhibitor, and AzadC, a DNA methyl-
transferase inhibitor. The expression of four selected
genes, Tjp1, Zic3, Ran and Cog8, were examined under dif-
ferent dosage of treatments for 1, 3 and 5 days. Zic3 and
Tjp1 were associated with repressive epigenetic markers
(Figure 5B and 5C), and their transcription in L1210
could not be detected with quantitative RT-PCR prior to
drug treatment (Figure 7A and 7B). AzadC alone was able
to de-repress Tjp1, but not Zic3. TSA alone did not reacti-
vate Tjp1 or Zic3. However, a combination of TSA and
Histone modifications and DNA methylation status in mouse  promoter regions Figure 4
Histone modifications and DNA methylation status 
in mouse promoter regions. A. Histogram of histone 
acetylation and dimethylation identified by ChIP-chip with 
mouse custom promoter array. Brown and green bars indi-
cate the frequency of acetyl-H3K9 and dimethyl-H3K9. Fre-
quency curves are shown as follows: continuous line, acetyl-
H3K9; dash line, dimethyl-H3K9. B. Interval plots of histone 
modifications versus DNA methylation. Histone modifica-
tions were plotted with two groups: unmethylated and meth-
ylated genes identified by RLGS. The interval bars indicate 
the distribution of histone modifications with horizontal lines 
at the endpoints of the 95% confidence interval for the mean 
and a symbol at the mean.
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AzadC was able to activate the expression of Zic3, and
showed a synergetic effect. For Tjp1, the addition of TSA,
however, had no or little additional effect on transcrip-
tion, and its re-expression was due to AzadC treatment.
Even though histone acetylation and DNA methylation
were closely correlated for both Tjp1 and Zic3, these two
epigenetic markers may affect gene function to differing
extents. These results are also consistent with previous
reports that DNA methylation is a dominant repressive
factor, and that TSA alone may not de-repress gene tran-
scription if the gene is densely methylated [15]. Two
genes, Ran and Cog8, were expressed in L1210 and not
methylated in their promoters (Figure 5B and 5C). The
expression of Ran was increased under low concentrations
(1–5 µM) of AzadC at day 1. However, both Ran and Cog8
showed reduced expression to varying degrees following
prolonged treatments (5 days) of AzadC and/or TSA (Fig-
ure 7C and 7D).
Discussion
The relationship between histone modifications and DNA
methylation in maintaining gene silencing has been stud-
ied at the chromosomal level [28]. The model shows that
a cooperation between methyl-H3K9 and DNA methyla-
tion is found in heterochromatin regions and major satel-
lite repeats [28]. In euchromatic regions or at the
individual gene level, controversial results have been
reported in regards to the distribution and function of his-
tone methylation in mammals [17,18,20-22].
Using genome-wide profiling techniques in L1210 leuke-
mia cells, our present study shows distinct levels of auton-
omy in histone modifications in relation to DNA
methylation of multiple protein-coding genes. Specifi-
cally, we demonstrate an inverse relationship between
DNA methylation and histone acetylation in regulating
transcription of these genes in mouse leukemia cells.
However, methyl-H3K9 seems to be ambiguous in speci-
fying silencing of some genes tested. Our findings might
The promoter landscape of histone modifications Figure 6
The promoter landscape of histone modifications. 
The fold enrichment by ChIP-chip with acetyl-H3K9 and 
dimethyl-H3K9 antibodies was screened by 12 sets of prim-
ers. The 12 PCR positions for each gene are indicated as the 
distances from transcription start site (0). Each error bar 
represents the standard deviation calculated from triplicates.
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not fit into the model that histone methylation and DNA
methylation are closely corollated in maintaining the
repressive state of genes [3]. It should be noted that the
establishment of this prior model is solely based on the
observation of a few genes [11,12,14,29,30]. The present
findings, however, are based on genome-wide profiling of
these epigenetic components in multiple genes. Here we
would like to propose an alternative model, in which his-
tone methylation is distributed throughout the whole
genome, including transcribed regions, and can be
reversed by histone demethylase. However, DNA methyl-
ation is the final repressive lock, which can not be easily
removed. In the "context" of stabilized chromatin, regions
of histone acetylation "islands" are used to keep the active
conformation at specific positions.
In addition to the above explanation, one additional sug-
gestion is that the promoter region of protein-coding
genes is not the prime target for this histone modification
(i.e., methyl-H3K9). Recent discoveries have shown that
the mouse promoter regions of hemoglobin beta adult major
chain and GATA-2 have lower levels of both di- and tri-
methylation of H3K9 than those in major satellite repeats
and transcribed regions [31]. It is possible that regulatory
mechanisms of histone methylation of H3K9, especially
its crosstalk with DNA methylation, are different depend-
ing on chromatin locations and other unknown factors.
Our data shows the diverse status of histone modifica-
tions in relation to DNA methylation in mouse leukemia
cells, providing new clues to the understanding of epige-
netic regulation in mouse genome. In this regard, epige-
netic components that specify active or inactive chromatin
play different roles, but are cooperative, under different
circumstances during mammalian development. Cross-
talk between H3K9 methylation and DNA methylation
are evolutionarily conserved from fungi to plants to mam-
mals [3,32]. While genetic studies have shown that while
H3K9 methylation is completely responsible for estab-
lishing DNA methylation in heterochromatic regions of
Neurospora, this correlation is only partially established in
Arabidopsis [6,7]. Meanwhile, some reports have shown
that the distribution of histone methylation is dependent
on DNA methylation in plants, but not in fungi [6,33]. In
mouse embryonic stem cells lacking Dnmt1, Dnmt3a or
Dnmt3b, no trimethyl-H3K9 redistribution is observed
[8]. In double-null mouse ES cells for Suv39h, a histone
methyltransferase, DNA methylation profiles are only
changed in pericentric satellite repeats, but not in other
repeat sequences [8]. Another histone methyltransferase,
G9a, specifically affects imprinted genes depending on the
development of embryonic stages [30]. Other gene studies
have also produced controversial results between the cor-
relation of histone modifications and DNA methylation
[11,34,35]. From these studies, it is obvious that epige-
netic redundancy, resulting from complex interactions
among different chromatin components, is implemented
to safeguard the stability of repressed chromatin structure.
Possible "heterogeneity" of epigenetic regulation is also
revealed by our TSA/AzadC treatment study. Repressive
epigenetic marks may be different in the 4 genes analyzed,
as the same drug treatment produced differential effects of
expression in these loci. Meanwhile, alternative pathways
may exist for TSA or AzadC that affect their upstream reg-
ulators genes, which also regulate the expression of these
genes.
Here we need to keep in mind that only dimethylation of
H3K9 was examined in this study, and further investiga-
tion is essential to delineate the relation of mono- and tri-
methyl-H3K9 methylation to DNA methylation. It is
known that in mouse, different types of methylation at
H3K9 are distributed with various patterns in chromatin
[3,32]. For example, trimethyl-H3K9 is over abundant in
heterochromatin, whereas mono- and dimethyl-H3K9 are
predominantly in euchromatin. Since we were more inter-
ested in the epigenetic modifications in euchromatin,
dimethyl-H3K9 was selected in this study. Both mono-
and trimethyl-H3K9 methylation deserve further study so
that "heterogeneity" of epigenetic regulation can be well
understood. We selected a single mouse leukemia cell
line, L1210, in this study and conclusions drawn in this
system will need to be validated in other mammalian
cells.
The effect of TSA and AzadC on gene expression Figure 7
The effect of TSA and AzadC on gene expression. 
L1210 cells were treated without or with TSA (300 nM for 
24 h), AzadC (1, 2.5 and 5 µM for 1, 3 and 5 days), or the 
combination of TSA and AzadC (1 µM of AzadC for 1, 3 and 
5 days followed by 300 nM of TSA for 24 h). Expression of 
targets were identified by quantitative RT-PCR. A and B. 
Zic3 and Tjp1 are methylated and associated with hypoacetyl-
H3K9. C and D. Ran and Cog8 are unmethylated and associ-
ated with hyperacetyl-H3K9. Each error bar represents the 
standard deviation calculated from triplicates.
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ChIP-chip, RLGS, and DMH are genome-wide techniques,
which can be readily applied to epigenomic studies. CpG
island arrays have been widely used in human epigenetic
studies [36]. However, very little work has been done
combining mouse CpG island arrays with other epige-
nomic tools. Current knowledge of crosstalk between his-
tone modifications and DNA methylation comes mainly
from a series of experimental strategies, including com-
plex interaction, genetic studies and sequence characteri-
zation [9]. In addition, one main direction is to delineate
specific epigenetic marks that implicate cellular functions,
such as cell-lineage determination and stem cell differen-
tiation. These challenges require epigenomic tools, as
those described in this study and two recent reviews
[3,32]. Studies have described the use of ChIP-chip to
investigate the correlation between histone modifications
and gene transcription from yeast to human [37]. Because
of technical limitations, few epigenomic tools have been
reported in the mouse. The implementation of CpG
island and custom microarrays makes it possible to inter-
rogate complex epigenetic networks in mammalian sys-
tems.
Conclusion
We have performed integrative epigenomic studies and
found a diverse relationship between histone modifica-
tions and DNA methylation for the maintenance of gene
silencing. Acetyl-H3K9 appears to have an inverse rela-
tionship with promoter methylation in protein-coding
genes. In contrast, methyl-H3K9 seems to be less dis-
tinctly related to promoter methylation. This work also
demonstrates the importance of using genome-wide
approaches to decipher complex epigenetic regulation in
the cell.
Methods
Cell culture
Mouse leukemia cell line L1210 (American Type Culture
Collection, Manassas, VA) was grown in Dulbecco's mod-
ified Eagle's medium (Cellgro, Herndon, VA) plus 10%
FBS in plastic tissue culture plates in a humidified atmos-
phere containing 5% CO2 at 37°C. The cells were grown
to 90% confluency before being harvested.
Chromatin immunoprecipitation microarray (ChIP-chip)
Five millions of L1210 cells were crosslinked with 1% for-
maldehyde for 10 min, and then 0.125 M glycine was
used to stop the crosslinking. Chromatin immunoprecip-
itation was performed by using ChIP assay kit (Upstate
Biotechnology, Charlottesville, VA) as described previ-
ously [38]. The antibodies against acetyl-H3K9 (AcH3K9,
06–942) and dimethyl-H3K9 (diMeH3K9, ab-7312) were
purchased from Upstate Biotechnology (Charlottesville,
VA) and Abcam (Cambridge, MA), respectively. Pooled
DNA (up to 10) from multiple ChIPs and input DNA were
labeled by Cy5 and Cy3 fluorescent dyes (Amersham,
Buckinghamshire, UK) and then were cohybridized to the
mouse 9.2k CpG island array (UHN microarray center,
Ontario, Canada) or mouse custom array. Post-hybridiza-
tion washes were performed as previously described [23].
The washed slides were scanned by a GenePix 4000A scan-
ner (Axon, Union City, CA), and the acquired microarray
images were analyzed with GenePix Pro 6.0 software
(Axon, Union City, CA). Duplicate hybridizations were
performed for each antibody and the quality of replicate
chips was examined by scatter plot and Pearson's correla-
tion analysis (from 0.77–0.82) [23]. After excluding the
spots flagged for bad quality, normalized Cy5/Cy3 ratios
of these loci were calculated by GenePix Pro 6.0 [38].
Differential methylation hybridization
Differential methylation hybridization (DMH) was per-
formed essentially as described ([23,38]). Briefly, 2 µg of
genomic DNA were digested by MseI to produce small
fragments and then H-24/H-12 PCR linkers (5'-
AGGCAACTGTGCTATCCGAGGGA T-3' and 5'-TAATC-
CCTCG-GA-3') were ligated to the digested DNA frag-
ments. The DNA samples were further digested with two
methylation-sensitive endonucleases, HpaII and BstUI,
and amplified by PCR reaction using H-24 as a primer.
After amplification, DNA from L1210 and DBA2 was
labeled with Cy5 and Cy3 dye, individually. Hybridiza-
tion and later analysis were performed as described above
in ChIP-chip section.
Mouse custom array
PCR was performed to amplify the promoter regions (-
700 bp to +300 bp from the transcription start site) with
mouse genomic DNA as template (see table S1). To ensure
the reproducibility of each PCR and to prevent nonspe-
cific amplification, PCR products (500-bp on average)
were individually verified by 1.2% agarose gel electro-
phoresis. PCR products and the control repetitive DNA
were then mixed with 50% dimethylsulfoxide and spotted
in triplicate to GAPS II coated slides (Corning, Acton, MA)
by Affymetrix/GMS 417 Arrayer (Affymetrix, Santa Clara,
CA). Arrays were incubated in a desiccator overnight.
Spotted DNA was rehydrated by holding slides over boil-
ing water for 5 seconds and then placed on a hot plate for
2 seconds. UV (300 mJ) cross-linking was used to immo-
bilize spotted DNA. Slides were then stored in a desiccator
at ambient temperature.
Restriction landmark genome scanning (RLGS)
High molecular weight DNA was extracted from L1210
cells and DBA2 mouse tissue. Subsequently, RLGS was
performed as previously described [39]. Paired RLGS pro-
files, obtained from L1210 and DBA2, were overlaid and
the difference between the two profiles was detected by
visual inspection. Analysis was independently validatedBMC Genomics 2007, 8:131 http://www.biomedcentral.com/1471-2164/8/131
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by at least one additional investigator. All selected targets
for ChIP-chip were analyzed by comparing the RLGS pro-
files from L1210 and DBA2.
Combined bisulfite restriction analysis (COBRA)
In vitro methylated DNA (representing 100% methylated
DNA) and the DNA from a DBA2 mouse (representing
0% methylated DNA) were used as controls. Two micro-
grams of DNA from L1210 cells was treated with 3 M
sodium bisulfite overnight and then amplified by PCR.
Primers were designed to amplify both methylated and
unmethylated alleles of sodium bisulfite-treated DNA.
PCR products were purified by the gel extraction kit (Qia-
gen, Valencia, CA) and then digested by BstUI (CG↓CG)
restriction enzyme (NEB, Ipswich, MA). The digested frag-
ments were separated on an 8% polyacrylamide gel. The
primers are listed in Table S3.
Chromatin immunoprecipitation-quantitative polymerase 
chain reaction
ChIP was conducted the same way as in ChIP-chip. DNA
pool from ChIP and input control was first measured by
spectrophotometer (NanoDrop, Wilmington, DE). Quan-
titative PCR with SYBR green-based detection (Applied
Biosystems, Foster City, CA) was performed as described
previously [40]. In brief, primers are designed according
the promoter structure of selected genes (Figure 5A).
Quantitative ChIP-PCR values were normalized against
values from a standard curve (50 to 0.08 ng, R2 > 0.99)
constructed by input DNA with the same primer sets. The
primers are listed in Table S3.
Trichostatin A (TSA) and 5-aza-2'-deoxycytidine (AzadC) 
treatment
Cells were split the day before treatment and then treated
with TSA (Sigma, St. Louis, MO), AzadC (Sigma, St. Louis,
MO) or the combination of the two drugs. 1, 2.5 and 5 µM
of AzadC in demethylsulfoxide was applied to cells every
24 h for 1, 3 or 5 days. 300 nM TSA in demethylsulfoxide
was used to treat cells for 24 h. For combination treat-
ment, 1 µM of AzadC daily for 1, 3 or 5 days was followed
with 300 nM TSA for 24 h. Cells treated with medium con-
taining dimethylsulfoxide served as a control.
Quantitative reverse transcription-polymerase chain 
reaction
Total RNA was extracted from drug treated and untreated
cells. Two µg RNA was first treated with DNase I (Invitro-
gen, Carlsbad, CA) to remove potential DNA contamina-
tion and then was reverse transcribed with SuperScript II
reverse transcriptase (Invitrogen, Carlsbad, CA). Quanti-
tative RT-PCR was performed by using SYBR green
(Applied Biosystems, Foster City, CA) as a marker for
DNA amplification on a 7500 Real-Time PCR System
apparatus (Applied Biosystems, Foster City, CA). The rel-
ative mRNA level of a given locus was calculated by rela-
tive quantitation of gene expression (Applied Biosystems,
Foster City, CA) with GAPDH mRNA (based on amplifi-
cation efficiency) as an internal control.
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